- Home
- WRN vs CLLS Comparison
WRN vs CLLS Comparison
Compare WRN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRN
- CLLS
- Stock Information
- Founded
- WRN 2006
- CLLS 1999
- Country
- WRN Canada
- CLLS France
- Employees
- WRN N/A
- CLLS N/A
- Industry
- WRN Metal Mining
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- WRN Basic Materials
- CLLS Health Care
- Exchange
- WRN Nasdaq
- CLLS Nasdaq
- Market Cap
- WRN 228.0M
- CLLS 143.4M
- IPO Year
- WRN N/A
- CLLS 2007
- Fundamental
- Price
- WRN $1.25
- CLLS $1.58
- Analyst Decision
- WRN Strong Buy
- CLLS Buy
- Analyst Count
- WRN 1
- CLLS 1
- Target Price
- WRN $4.00
- CLLS $4.00
- AVG Volume (30 Days)
- WRN 344.1K
- CLLS 54.7K
- Earning Date
- WRN 08-08-2025
- CLLS 08-05-2025
- Dividend Yield
- WRN N/A
- CLLS N/A
- EPS Growth
- WRN N/A
- CLLS N/A
- EPS
- WRN N/A
- CLLS N/A
- Revenue
- WRN N/A
- CLLS $54,747,000.00
- Revenue This Year
- WRN N/A
- CLLS $48.52
- Revenue Next Year
- WRN N/A
- CLLS $5.17
- P/E Ratio
- WRN N/A
- CLLS N/A
- Revenue Growth
- WRN N/A
- CLLS 351.26
- 52 Week Low
- WRN $0.90
- CLLS $1.10
- 52 Week High
- WRN $1.42
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- WRN 50.93
- CLLS 64.58
- Support Level
- WRN $1.18
- CLLS $1.41
- Resistance Level
- WRN $1.26
- CLLS $1.65
- Average True Range (ATR)
- WRN 0.06
- CLLS 0.10
- MACD
- WRN -0.01
- CLLS 0.03
- Stochastic Oscillator
- WRN 29.55
- CLLS 93.81
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.